The China lung cancer therapeutics market size is anticipated to reach USD 5.34 billion by 2030 and is projected to grow at a CAGR of 13.7% from 2024 to 2030. Increasing incidence of lung cancer, growing awareness and screening initiatives, and adoption of targeted therapies in the country is projected to drive the market growth over the forecast years.
In June 2024, the FLAURA2 clinical trial investigated the efficacy of Tagrisso (osimertinib) in combination with chemotherapy compared to standard care for patients with advanced non-small cell lung cancer (NSCLC), particularly focusing on a cohort of Chinese patients. The results demonstrated that this combination therapy significantly reduced the risk of disease progression or death by nearly 50%. This finding is pivotal as it indicates a substantial improvement in patient outcomes, which is anticipated to influence treatment protocols and market dynamics.
The Chinese government has recognized the growing burden of cancer and has taken significant steps to enhance funding and support for research. Initiatives from organizations such as the National Natural Science Foundation of China (NSFC) and the National Major Scientific and Technological Special Project for “Significant New Drugs Development” are aimed at fostering innovation in drug development. This governmental backing is crucial in driving advancements in therapeutics.
This product will be delivered within 1-3 business days.
In June 2024, the FLAURA2 clinical trial investigated the efficacy of Tagrisso (osimertinib) in combination with chemotherapy compared to standard care for patients with advanced non-small cell lung cancer (NSCLC), particularly focusing on a cohort of Chinese patients. The results demonstrated that this combination therapy significantly reduced the risk of disease progression or death by nearly 50%. This finding is pivotal as it indicates a substantial improvement in patient outcomes, which is anticipated to influence treatment protocols and market dynamics.
The Chinese government has recognized the growing burden of cancer and has taken significant steps to enhance funding and support for research. Initiatives from organizations such as the National Natural Science Foundation of China (NSFC) and the National Major Scientific and Technological Special Project for “Significant New Drugs Development” are aimed at fostering innovation in drug development. This governmental backing is crucial in driving advancements in therapeutics.
China Lung Cancer Therapeutics Market Report Highlights
- Based on disease type, the NSCLC segment led the market with the largest revenue share of 84.27% in 2023, driven by the increasing smoking rates
- Based on therapeutic class, the targeted therapy segment led the market with the largest revenue share of 39.1% in 2023. The growth is attributed to the increasing prevalence of cancer within the population which has created an urgent need for more effective treatment options
- In December 2023, Simcere Zaiming Pharmaceutical Co., Ltd. announced a significant development regarding COSELA (Trilaciclib Hydrochloride for Injection), an innovative oncology product that is co-developed with G1 Therapeutics. The approval notice from the National Medical Products Administration of China (NMPA) for the Supplementary Application of Drugs marks a pivotal moment for this medication, which is designed to improve outcomes for patients
The leading players in the China Lung Cancer Therapeutics market include:
- AstraZeneca
- Roche
- Pfizer
- Novartis
- Merck & Co.
- Bristol-Myers Squibb
- Eli Lilly and Company
- Boehringer Ingelheim
- Johnson & Johnson (Janssen Pharmaceuticals)
- BeiGene
- Innovent Biologics
- Jiangsu Hengrui Medicine Co., Ltd.
- China National Pharmaceutical Group (Sinopharm)
- Shanghai Junshi Biosciences Co., Ltd.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. China Lung Cancer Therapeutics Market Variables, Trends & Scope
Chapter 4. China Lung Cancer Therapeutics Market: Disease Type Estimates & Trend Analysis
Chapter 5. China Lung Cancer Therapeutics Market: Therapeutics Class Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the China Lung Cancer Therapeutics market include:- AstraZeneca
- Roche
- Pfizer
- Novartis
- Merck & Co.
- Bristol-Myers Squibb
- Eli Lilly and Company
- Boehringer Ingelheim
- Johnson & Johnson (Janssen Pharmaceuticals)
- BeiGene
- Innovent Biologics
- Jiangsu Hengrui Medicine Co., Ltd.
- China National Pharmaceutical Group (Sinopharm)
- Shanghai Junshi Biosciences Co., Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.18 Billion |
| Forecasted Market Value ( USD | $ 5.34 Billion |
| Compound Annual Growth Rate | 13.7% |
| Regions Covered | China |
| No. of Companies Mentioned | 15 |
